SeraNovo has acquired a €30,000 loan from the Enterprise Leiden Fund to develop our drug formulation platform. The loan is to be used to develop the second phase of the technology with a view to creating a market ready service with and ultimately a product line in the coming years.
The Enterprise Leiden Fund was set up by Luris to help companies, such as SeraNovo, to bring breakthrough innovations to the market. One member of the judging panel noted, ‘SeraNovo have an excellent technology capable of solving very difficult technical challenges in the pharmaceutical industries. We have every confidence in the team they have assembled and expect their impressive rate of development to continue.’